Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with Entinostat in Recurrent Ovarian Cancer
NCT03924245Phase 1Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 60 days. Started Oct 2020; status: terminated.
02
Drugs
entinostat
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03924245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924245.